Evidence map›Paper›PMID 40597358›Full record

ArticleOrphanet journal of rare diseases2025

A novel TIMM8A mutation in Mohr-Tranebjaerg syndrome without hearing loss and with basal ganglia iron deposition.

Ignacio Ventura, Francisco Revert-Ros, Fernando Revert, Jesús Ángel Prieto-Ruiz, José Miguel Hernández-Andreu

Abstract readCase Reports
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ignacio VenturaGrupo de Medicina Molecular y Mitocondrial, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, c/Quevedo 2, Valencia, 46001, Spain.
Francisco Revert-RosGrupo de Medicina Molecular y Mitocondrial, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, c/Quevedo 2, Valencia, 46001, Spain.
Fernando RevertGrupo de Medicina Molecular y Mitocondrial, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, c/Quevedo 2, Valencia, 46001, Spain.
Jesús Ángel Prieto-RuizGrupo de Medicina Molecular y Mitocondrial, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, c/Quevedo 2, Valencia, 46001, Spain. jesus.prieto@ucv.es.ORCID http://orcid.org/0000-0003-2726-7963
José Miguel Hernández-AndreuGrupo de Medicina Molecular y Mitocondrial, Facultad de Medicina y Ciencias de la Salud, Universidad Católica de Valencia San Vicente Mártir, c/Quevedo 2, Valencia, 46001, Spain.

Funding

Universidad Católica de Valencia San Vicente Màrtir UCV INGENIO PROGRAM, grant # 2024-168-092
6 · The paper itself

Abstract

Mohr-Tranebjaerg syndrome (MTS) is a rare X-linked recessive neurodegenerative disorder caused by pathogenic variants in the TIMM8A gene. TIMM8A, also known as Deafness-Dystonia Peptide-1 (DDP1) is a mitochondrial intermembrane space protein involved in the import and insertion of hydrophobic membrane proteins from the cytoplasm into the mitochondrial inner membrane. MTS typically presents early-onset progressive hearing loss, dystonia, visual impairment, and cognitive decline. Here, we report a case of a male adolescent with a previously undescribed variant in TIMM8A, associated with progressive dystonia but no hearing loss, highlighting the clinical variability of MTS. A 16-year-old male was referred for genetic evaluation due to a 6-year history of progressive dystonia, motor coordination difficulties, and iron deposits in the basal ganglia detected by brain MRI. Family history revealed mild motor abnormalities in his maternal uncle and recurrent muscle spasms in his mother. Whole-exome sequencing (WES) identified a c.98_101dupAGCA variant in TIMM8A in hemizygosity, classified as likely pathogenic. This variant causes a frameshift leading to a truncated protein. The patient inherited the variant from his mother, who is heterozygous for the mutation. Although the patient lacks the characteristic early-onset hearing loss seen in MTS, his neurological presentation and the imaging findings are consistent with the syndrome. This case underscores the phenotypic heterogeneity of Mohr-Tranebjaerg syndrome, where patients may present with prominent neurological symptoms such as dystonia without the hallmark auditory dysfunction. The identification of a novel TIMM8A variant expands the mutational spectrum of this rare disorder and provides insights into genotype-phenotype correlations. The absence of hearing loss in this patient raises important questions about the variability in the expression of the mutated TIMM8A. This report highlights a novel TIMM8A mutation associated with Mohr-Tranebjaerg syndrome, presenting primarily with dystonia and iron accumulation in the basal ganglia. The findings contribute to the understanding of the clinical spectrum of MTS and emphasize the importance of genetic testing in patients with unexplained progressive neurological symptoms.

Indexed as

Basal GangliaIronMitochondrial Precursor Protein Import Complex ProteinsOptic AtrophyAdolescentDeaf-Blind DisordersDystoniaHearing LossHumansIntellectual DisabilityMaleMutationIronMitochondrial Precursor Protein Import Complex ProteinsTIMM8A protein, humanBasal gangliaDystoniaIron depositionIron metabolism dysregulationMitochondrial dysfunctionMohr-Tranebjaerg syndromeNeurodegenerative disordersSusceptibility-weighted imaging (SWI)TIMM8A mutationWhole-exome sequencing (WES)

Identifiers

PMID40597358
PMCPMC12211147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.